Literature DB >> 16898072

Pharmacokinetics, tissue distribution and excretion of vinflunine.

Xiao-Ping Zhao1, Xiao-Quan Liu, Yong-Sheng Wang, Huan Wang, Guang-Ji Wang.   

Abstract

The plasma pharmacokinetics, tissue distribution, excretion and binding to plasma proteins of vinflunine, were investigated after intravenous (iv) administration. We obtained plasma profiles after iv administration of vinflunine at the doses of 3.5, 7 and 14 mg/kg in rats. The t1/2 values for vinflunine were estimated to be 18.38+/-1.20, 17.05+/-0.77, 18.35+/-1.57 h, and the mean AUC0-t values were 3.48+/-0.38, 6.54+/-0.68, 12.79+/-2.93 microg x h/ml, respectively. Of the various tissues tested, vinflunine was widely distributed into tissues, with the highest concentrations of vinflunine being found in well perfused organs. Maximal concentration of vinflunine was reached at 0.5 h postdose in the majority of tissues. In tumor-bearing mice, the similar pattern of tissue distribution was observable, except that vinflunine can be distributed into tumor. The binding of vinflunine in human and rat plasma proteins were 39.6% and 58.4% respectively. Within 96 h after administration, 9.58%, 15.36% and 0.71% of the given dose was excreted in urine, feces and bile, respectively. In conclusion, Vinflunine had a longer terminal half-life, a wide tissue distribution and less than 25% of the given dose was excreted as unchanged drug, suggesting metabolism as a major style of elimination.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16898072     DOI: 10.1007/BF03191120

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  15 in total

1.  Mechanism of inhibition of cell proliferation by Vinca alkaloids.

Authors:  M A Jordan; D Thrower; L Wilson
Journal:  Cancer Res       Date:  1991-04-15       Impact factor: 12.701

2.  Kinetic analysis of tubulin exchange at microtubule ends at low vinblastine concentrations.

Authors:  M A Jordan; L Wilson
Journal:  Biochemistry       Date:  1990-03-20       Impact factor: 3.162

3.  Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid.

Authors:  A Kruczynski; F Colpaert; J P Tarayre; P Mouillard; J Fahy; B T Hill
Journal:  Cancer Chemother Pharmacol       Date:  1998       Impact factor: 3.333

Review 4.  Vinorelbine: an overview.

Authors:  S A Johnson; P Harper; G N Hortobagyi; P Pouillart
Journal:  Cancer Treat Rev       Date:  1996-03       Impact factor: 12.111

Review 5.  Optimising treatment outcomes: a review of current management strategies in first-line chemotherapy of metastatic breast cancer.

Authors:  J Crown
Journal:  Eur J Cancer       Date:  1997-08       Impact factor: 9.162

Review 6.  Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties.

Authors:  A Kruczynski; B T Hill
Journal:  Crit Rev Oncol Hematol       Date:  2001-11       Impact factor: 6.312

7.  Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts.

Authors:  B T Hill; H H Fiebig; W R Waud; M F Poupon; F Colpaert; A Kruczynski
Journal:  Eur J Cancer       Date:  1999-03       Impact factor: 9.162

8.  Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid.

Authors:  A Kruczynski; J M Barret; C Etiévant; F Colpaert; J Fahy; B T Hill
Journal:  Biochem Pharmacol       Date:  1998-03-01       Impact factor: 5.858

9.  Vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro.

Authors:  C Etievant; J M Barret; A Kruczynski; D Perrin; B T Hill
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

10.  Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model.

Authors:  S E Holwell; B T Hill; M C Bibby
Journal:  Br J Cancer       Date:  2001-01       Impact factor: 7.640

View more
  1 in total

Review 1.  Vinflunine.

Authors:  James E Frampton; Marit D Moen
Journal:  Drugs       Date:  2010-07-09       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.